Cargando…

Single-Ascending-Dose Pharmacokinetic Study of Tribendimidine in Opisthorchis viverrini-Infected Patients

Praziquantel is the only drug available for the treatment of Opisthorchis viverrini infections. Tribendimidine has emerged as a potential treatment alternative; however, its pharmacokinetic (PK) properties have not been sufficiently studied to date. Via two phase IIa dose-finding studies, 68 O. vive...

Descripción completa

Detalles Bibliográficos
Autores principales: Duthaler, Urs, Sayasone, Somphou, Vanobbergen, Fiona, Penny, Melissa A., Odermatt, Peter, Huwyler, Jörg, Keiser, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5038241/
https://www.ncbi.nlm.nih.gov/pubmed/27431234
http://dx.doi.org/10.1128/AAC.00992-16
_version_ 1782455875868295168
author Duthaler, Urs
Sayasone, Somphou
Vanobbergen, Fiona
Penny, Melissa A.
Odermatt, Peter
Huwyler, Jörg
Keiser, Jennifer
author_facet Duthaler, Urs
Sayasone, Somphou
Vanobbergen, Fiona
Penny, Melissa A.
Odermatt, Peter
Huwyler, Jörg
Keiser, Jennifer
author_sort Duthaler, Urs
collection PubMed
description Praziquantel is the only drug available for the treatment of Opisthorchis viverrini infections. Tribendimidine has emerged as a potential treatment alternative; however, its pharmacokinetic (PK) properties have not been sufficiently studied to date. Via two phase IIa dose-finding studies, 68 O. viverrini patients were treated with 25- to 600-mg doses of tribendimidine using 50- and 200-mg tablet formulations. Plasma, blood, and dried blood spots (DBS) were sampled at selected time points. The two main metabolites of tribendimidine, active deacetylated amidantel (dADT) and acetylated dADT (adADT), were analyzed in plasma, blood, and DBS. PK parameters were estimated by noncompartmental analysis. An acceptable agreement among plasma and DBS concentrations was observed, with a mean bias of ≤10%, and 60% dADT and 74% adADT concentrations being within ±20% margins. We found that 200-mg tribendimidine tablets possess immediate floating characteristics, which led to variable time to maximal concentration of drug (T(max)) values (2 to 24 h) between individuals. Dose proportionality was observed for dADT from 25 to 200 mg using 50-mg tablets, but at higher dosages (200 to 600 mg), saturation occurred. The median ratio of the area under the plasma concentration-time curve from 0 to 24 h (AUC(0–24)) of dADT to the AUC(0–)(24) of adADT ranged from 0.8 to 26.4, suggesting substantial differences in acetylation rates. Cure rates ranged from 11% (25-mg dose) to 100% (400-mg dose). Cured patients showed significantly higher dADT maximal serum concentrations (C(max)) and AUC(0–24) values than uncured patients. Tribendimidine is a promising drug for the treatment of opisthorchiasis. However, the tablet formulation should be optimized to achieve consistent absorption among patients. Further studies are warranted to assess the large differences between individuals in the rate of metabolic turnover of dADT to adADT. (This study has been registered with the ISRCTN Registry under no. ISRCTN96948551.)
format Online
Article
Text
id pubmed-5038241
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-50382412016-10-13 Single-Ascending-Dose Pharmacokinetic Study of Tribendimidine in Opisthorchis viverrini-Infected Patients Duthaler, Urs Sayasone, Somphou Vanobbergen, Fiona Penny, Melissa A. Odermatt, Peter Huwyler, Jörg Keiser, Jennifer Antimicrob Agents Chemother Experimental Therapeutics Praziquantel is the only drug available for the treatment of Opisthorchis viverrini infections. Tribendimidine has emerged as a potential treatment alternative; however, its pharmacokinetic (PK) properties have not been sufficiently studied to date. Via two phase IIa dose-finding studies, 68 O. viverrini patients were treated with 25- to 600-mg doses of tribendimidine using 50- and 200-mg tablet formulations. Plasma, blood, and dried blood spots (DBS) were sampled at selected time points. The two main metabolites of tribendimidine, active deacetylated amidantel (dADT) and acetylated dADT (adADT), were analyzed in plasma, blood, and DBS. PK parameters were estimated by noncompartmental analysis. An acceptable agreement among plasma and DBS concentrations was observed, with a mean bias of ≤10%, and 60% dADT and 74% adADT concentrations being within ±20% margins. We found that 200-mg tribendimidine tablets possess immediate floating characteristics, which led to variable time to maximal concentration of drug (T(max)) values (2 to 24 h) between individuals. Dose proportionality was observed for dADT from 25 to 200 mg using 50-mg tablets, but at higher dosages (200 to 600 mg), saturation occurred. The median ratio of the area under the plasma concentration-time curve from 0 to 24 h (AUC(0–24)) of dADT to the AUC(0–)(24) of adADT ranged from 0.8 to 26.4, suggesting substantial differences in acetylation rates. Cure rates ranged from 11% (25-mg dose) to 100% (400-mg dose). Cured patients showed significantly higher dADT maximal serum concentrations (C(max)) and AUC(0–24) values than uncured patients. Tribendimidine is a promising drug for the treatment of opisthorchiasis. However, the tablet formulation should be optimized to achieve consistent absorption among patients. Further studies are warranted to assess the large differences between individuals in the rate of metabolic turnover of dADT to adADT. (This study has been registered with the ISRCTN Registry under no. ISRCTN96948551.) American Society for Microbiology 2016-09-23 /pmc/articles/PMC5038241/ /pubmed/27431234 http://dx.doi.org/10.1128/AAC.00992-16 Text en Copyright © 2016 Duthaler et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (http://creativecommons.org/licenses/by/4.0/) .
spellingShingle Experimental Therapeutics
Duthaler, Urs
Sayasone, Somphou
Vanobbergen, Fiona
Penny, Melissa A.
Odermatt, Peter
Huwyler, Jörg
Keiser, Jennifer
Single-Ascending-Dose Pharmacokinetic Study of Tribendimidine in Opisthorchis viverrini-Infected Patients
title Single-Ascending-Dose Pharmacokinetic Study of Tribendimidine in Opisthorchis viverrini-Infected Patients
title_full Single-Ascending-Dose Pharmacokinetic Study of Tribendimidine in Opisthorchis viverrini-Infected Patients
title_fullStr Single-Ascending-Dose Pharmacokinetic Study of Tribendimidine in Opisthorchis viverrini-Infected Patients
title_full_unstemmed Single-Ascending-Dose Pharmacokinetic Study of Tribendimidine in Opisthorchis viverrini-Infected Patients
title_short Single-Ascending-Dose Pharmacokinetic Study of Tribendimidine in Opisthorchis viverrini-Infected Patients
title_sort single-ascending-dose pharmacokinetic study of tribendimidine in opisthorchis viverrini-infected patients
topic Experimental Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5038241/
https://www.ncbi.nlm.nih.gov/pubmed/27431234
http://dx.doi.org/10.1128/AAC.00992-16
work_keys_str_mv AT duthalerurs singleascendingdosepharmacokineticstudyoftribendimidineinopisthorchisviverriniinfectedpatients
AT sayasonesomphou singleascendingdosepharmacokineticstudyoftribendimidineinopisthorchisviverriniinfectedpatients
AT vanobbergenfiona singleascendingdosepharmacokineticstudyoftribendimidineinopisthorchisviverriniinfectedpatients
AT pennymelissaa singleascendingdosepharmacokineticstudyoftribendimidineinopisthorchisviverriniinfectedpatients
AT odermattpeter singleascendingdosepharmacokineticstudyoftribendimidineinopisthorchisviverriniinfectedpatients
AT huwylerjorg singleascendingdosepharmacokineticstudyoftribendimidineinopisthorchisviverriniinfectedpatients
AT keiserjennifer singleascendingdosepharmacokineticstudyoftribendimidineinopisthorchisviverriniinfectedpatients